Lupin's Robust First Quarter: Net Profit Surges by 77%

Drug maker Lupin reported a 77% increase in consolidated net profit, reaching Rs 801 crore in Q1 FY25. This growth was driven by strong sales across key markets, including a significant rise in North American and Indian revenues. The company's total Q1 revenue was Rs 5,600 crore.

Drug maker Lupin has reported a striking 77% surge in consolidated net profit, reaching Rs 801 crore for the quarter ending June 30, 2024. This substantial increase was primarily fueled by robust sales across multiple markets.

In comparison, the Mumbai-based company had logged a net profit of Rs 452 crore in the corresponding quarter of the previous fiscal year. Total revenue from operations climbed to Rs 5,600 crore, up from Rs 4,814 crore in the June quarter of FY24, according to a regulatory filing released on Tuesday evening.

'We have had a strong quarter on the back of the momentum we built through FY24, with performance driven by new products, key geographies, and improvement in our operating margin and profitability,' Lupin Ltd Managing Director Nilesh Gupta stated. He added that the firm is on track for sustained growth, citing enhancements in sales, commercial, and operating efficiencies, alongside a solid compliance framework. Notably, sales in North America rose by 28% to Rs 2,041 crore, while Indian sales climbed to Rs 1,926 crore, reflecting a resilient performance in core markets.

(With inputs from agencies.)